ANIP (ANI Pharmaceuticals, Inc.) Stock Financials & Earnings

ANIPANI Pharmaceuticals, Inc.

Mkt Cap$2B

Revenue (TTM)$883M

Net Income (TTM)$76M

EPS (TTM)$3.35

Free Cash Flow (TTM)$128M

Gross Margin69.1%

Op. Margin12.6%

Net Margin8.6%

FCF Margin14.5%

P/S Ratio (TTM)1.9x

P/E Ratio (TTM)22.5x

YoY Rev Growth+43.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$107M	$69M	$10M
Q2 23	$117M	$74M	$12M
Q3 23	$132M	$84M	$18M
Q4 23	$132M	$78M	$7M
Q1 24	$137M	$88M	$20M
Q2 24	$138M	$80M	$5M
Q3 24	$148M	$85M	-$21M
Q4 24	$191M	$110M	-$4M
Q1 25	$197M	$124M	$26M
Q2 25	$211M	$137M	$14M
Q3 25	$228M	$112M	$23M
Q4 25	$247M	$238M	$48M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Revenue Segments

Quarter	Generics, Established Brands, and Other	Rare Disease	Sales of Established Brands	Sales of rare disease pharmaceutical products	Total Sales of Generics and Other
Q1 23	$90M	$16M	—	—	—
Q2 23	$92M	$24M	—	—	—
Q3 23	$102M	$30M	—	—	—
Q1 24	$100M	$37M	—	—	—
Q2 24	$89M	$49M	—	—	—
Q3 24	$92M	$56M	—	—	—
Q1 25	—	—	$25M	$69M	$103M
Q2 25	—	—	$13M	$104M	$94M
Q3 25	—	—	$11M	$118M	$99M
Q4 25	—	—	$12M	$131M	$103M

Revenue by Geography

Quarter	Canada	United States	Non-US
Q1 23	$565K	$106M	—
Q2 23	—	$117M	—
Q3 23	—	$132M	—
Q4 23	—	$132M	—
Q1 24	—	$137M	—
Q2 24	—	$138M	—
Q3 24	—	$147M	$1M
Q4 24	—	$182M	$8M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$68M	$0	$68M
Q2 23	$162M	$0	$162M
Q3 23	$193M	$0	$193M
Q4 23	$221M	$0	$221M
Q1 24	$229M	$10M	$238M
Q2 24	$240M	$7M	$247M
Q3 24	$145M	$8M	$153M
Q4 24	$145M	$6M	$151M
Q1 25	$150M	$5M	$155M
Q2 25	$218M	$6M	$224M
Q3 25	$263M	$0	$263M
Q4 25	$286M	$0	$286M

Shares Outstanding

Revenue Per Employee

Revenue / Employee